| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT06717126 | A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal… | Uveal Melanoma | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06644183 | Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic… | Leukemia | Recruiting |
| NCT07018752 | A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas | Peripheral T Cells Lymphoma (PTCL) | Recruiting |
| NCT06887803 | A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis… | Myelofibrosis (MF) | Recruiting |
| NCT06879717 | A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without… | Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Active, Not Recruiting |
| Phase 1 | |||
| NCT07203391 | Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis | Uveal Melanoma, Metastatic | Recruiting |
| NCT04328844 | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | Solid Tumor, Adult | Active, Not Recruiting |